SuppreMol looks for partner as 'long-lasting' ITP candidate shows clinical promise
This article was originally published in Scrip
Interim results from SuppreMol's Phase Ib/IIa trial of SM101 to treat primary immune thrombocytopenia (ITP) have provided encouraging efficacy data, prompting the German company to start looking for a pharma partner to develop the drug candidate "in further indications such as rheumatoid arthritis (RA) or multiple sclerosis (MS) or/and support the ongoing programme, which includes a Phase IIa trial in systemic lupus erythematosus (SLE) started last year, with additional funding", CEO Professor Peter Buckel told Scrip.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.